KRYS (Krystal Biotech, Inc.) מחיר לרווח עתידי

Krystal Biotech, Inc. (KRYS) is implementing advanced gene therapy, yet faces logistical complexities and pressure from insurers. The company's forward P/E ratio visualizes market expectations, with the current figure standing at 33.00. Growth is driven by the commercialization of Vyjuvek and the development of the STAR-D platform. Explosive demand for the drug creates strong momentum, although a portion of the positive forecasts is already priced in.

Forward P/E compares the current market value of shares with projected net income, allowing an investor to assess the extent of overpayment for future cash flows and operational efficiency. For Krystal Biotech, Inc. (KRYS), whose monopoly in gene therapy ensures exceptional margins and stable FCF, the company's future P/E ratio serves as an indicator of the asset's fair value relative to its expansion rates.